Cargando…
T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621504/ http://dx.doi.org/10.1097/01.HS9.0000890916.12776.84 |
| _version_ | 1784821571574038528 |
|---|---|
| author | Castellino, Sharon M. Pei, Qinglin Parsons, Susan K. Hodgson, David Mccarten, Kathleen Horton, Terzah Cho, Steve Wu, Yue Punnett, Angela Dave, Hema Henderson, Tara O. Hoppe, Bradford S. Charpentier, Ann-Marie Keller, Frank G. Kelly, Kara M. |
| author_facet | Castellino, Sharon M. Pei, Qinglin Parsons, Susan K. Hodgson, David Mccarten, Kathleen Horton, Terzah Cho, Steve Wu, Yue Punnett, Angela Dave, Hema Henderson, Tara O. Hoppe, Bradford S. Charpentier, Ann-Marie Keller, Frank G. Kelly, Kara M. |
| author_sort | Castellino, Sharon M. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9621504 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96215042022-11-01 T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma Castellino, Sharon M. Pei, Qinglin Parsons, Susan K. Hodgson, David Mccarten, Kathleen Horton, Terzah Cho, Steve Wu, Yue Punnett, Angela Dave, Hema Henderson, Tara O. Hoppe, Bradford S. Charpentier, Ann-Marie Keller, Frank G. Kelly, Kara M. Hemasphere Pediatric HL Lippincott Williams & Wilkins 2022-10-03 /pmc/articles/PMC9621504/ http://dx.doi.org/10.1097/01.HS9.0000890916.12776.84 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Pediatric HL Castellino, Sharon M. Pei, Qinglin Parsons, Susan K. Hodgson, David Mccarten, Kathleen Horton, Terzah Cho, Steve Wu, Yue Punnett, Angela Dave, Hema Henderson, Tara O. Hoppe, Bradford S. Charpentier, Ann-Marie Keller, Frank G. Kelly, Kara M. T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma |
| title | T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma |
| title_full | T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma |
| title_fullStr | T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma |
| title_full_unstemmed | T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma |
| title_short | T087: Brentuximab vedotin (Bv) Demonstrates Superior Event-Free Survival in Pediatric High-Risk Hodgkin Lymphoma |
| title_sort | t087: brentuximab vedotin (bv) demonstrates superior event-free survival in pediatric high-risk hodgkin lymphoma |
| topic | Pediatric HL |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621504/ http://dx.doi.org/10.1097/01.HS9.0000890916.12776.84 |
| work_keys_str_mv | AT castellinosharonm t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT peiqinglin t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT parsonssusank t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT hodgsondavid t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT mccartenkathleen t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT hortonterzah t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT chosteve t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT wuyue t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT punnettangela t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT davehema t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT hendersontarao t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT hoppebradfords t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT charpentierannmarie t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT kellerfrankg t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma AT kellykaram t087brentuximabvedotinbvdemonstratessuperioreventfreesurvivalinpediatrichighriskhodgkinlymphoma |